Calcium channel blockers in the prevention of end stage renal disease: a review.

about

Transplantation as a therapeutic option for diabetic nephropathy.1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.

P2860

Q35907520-203339D4-D971-4860-B513-1F31BFA309AC Q38125687-1BB8556D-1737-46BE-BBB9-B5905BE8B491

P2860

Calcium channel blockers in the prevention of end stage renal disease: a review.

Item

http://www.wikidata.org/entity/Q35738806

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Calcium channel blockers in the prevention of end stage renal disease: a review.

@ast

Calcium channel blockers in the prevention of end stage renal disease: a review.

@en

type

Item

label

Calcium channel blockers in the prevention of end stage renal disease: a review.

@ast

Calcium channel blockers in the prevention of end stage renal disease: a review.

@en

prefLabel

Calcium channel blockers in the prevention of end stage renal disease: a review.

@ast

Calcium channel blockers in the prevention of end stage renal disease: a review.

@en

P1476

Calcium channel blockers in the prevention of end stage renal disease: a review.

@en

P2093

A Derwa

http://www.w3.org/2001/XMLSchema#string

P Peeters

http://www.w3.org/2001/XMLSchema#string

R Vanholder

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

Calcium-antagonist drugs.

Calcium channel blockers - the effect on renal changes in clinical and experimental diabetes: an overview.

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Renoprotective therapy in patients with nondiabetic nephropathies.

Molecular basis of glomerular permselectivity.

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition.

P304

44-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/ACB.2004.007

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8635291

http://www.w3.org/2001/XMLSchema#string

P698

15065696

http://www.w3.org/2001/XMLSchema#string

Calcium channel blockers in the prevention of end stage renal disease: a review.

about

P2860

P2860

Calcium channel blockers in the prevention of end stage renal disease: a review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698